Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774784 · ClinicalTrials.gov registry record
A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease
A clinical trial, sponsored by Alnylam Pharmaceuticals.
- Terminated
- Registry status
- 26
- Enrollment target
NCT03774784 is a clinical trial that was terminated before completion, run by Alnylam Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT03774784 was terminated before completion, sponsored by Alnylam Pharmaceuticals.
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospective chart review data and biological specimens at baseline only. Other participants, in addition to retrospective chart review, will be followed prospectively.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2019-01-29 |
| Est. Completion | 2020-05-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03774784
The ClinicalTrials.gov registry entry for NCT03774784 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03774784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03774784 about?
NCT03774784 is a clinical study titled "A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease". The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospe...
What is the current status of trial NCT03774784?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 2019-01-29. Estimated completion is 2020-05-18.
Who is sponsoring clinical trial NCT03774784?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.